1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Shanghai Titan Scientific Co. Ltd. Class A

Shanghai Titan Scientific Co. Ltd. Class A

SSSE:688133
18.57
CNY
+0.71
(+3.98%)
-0.57EPS
3.47BMarket Cap
Oct 30Next Earn
Shanghai Titan Scientific Co. Ltd. Class A
SSE:688133
(Shanghai Stock Exchange)

Recent

price

18.57

P/E

ratio

- -

div

yld

1.46%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.74
2.48
3.29
4.77
7.3
9.46
11.03
11.69
14.5
23.58
23.66
17.89
15.49
15.59
Revenue per Share
0.11
0.09
0.2
0.32
0.42
0.61
0.71
0.87
0.96
1.13
0.62
0.08
-0.19
-0.49
Basic EPS, GAAP
-0.54
0.09
-0.21
-0.12
0.08
0.13
-0.59
-1.98
-2.53
-4.08
-5.04
-1.81
-0.29
- -
Free Cash Flow per Basic Share
0.03
0.04
0.04
0.03
0.26
0.26
0.31
0.07
0.26
0.37
0.41
0.35
0.35
0.27
Dividend per Share
1.06
1.13
1.82
2.07
2.96
3.73
5.03
9.62
10.55
16.51
16.9
16.94
16.74
16.5
Book Value per Share
1.06
1.13
1.82
2.07
2.93
3.69
4.99
9.38
9.27
14.73
15.1
14.74
14.79
14.61
Tangible Book Value per Share
76
76
82
86
91
98
104
118
149
111
117
161
163
164
Basic Weighted Avg Shares
133
187
268
409
664
926
1,144
1,384
2,164
2,608
2,770
2,884
2,521
2,554
Sales/Revenue/Turnover
5.08
5.07
7.64
8.33
7.44
8.41
8.71
9.18
8.11
7.71
4.19
2.29
0.6
-0.84
Operating Margin (%)
1
3
3
3
4
6
7
10
20
37
60
84
100
- -
Depreciation Expense
8
7
17
28
39
60
74
103
144
125
73
13
-31
-80
Net Income, GAAP
12.38
15.72
14.16
11.81
11.17
11.26
12.13
13.21
16.16
12.82
11.6
- -
- -
- -
Effective Tax Rate (%)
6.09
3.71
6.21
6.74
5.8
6.47
6.48
7.42
6.65
4.79
2.62
0.45
-1.23
-3.14
Profit Margin (%)
70
75
141
163
240
324
477
1,305
1,241
2,250
1,960
1,683
1,445
1,362
Working Capital
- -
- -
- -
- -
- -
- -
- -
22
116
294
357
460
462
443
LT Debt
103
110
176
201
287
387
564
1,454
1,616
2,767
2,850
2,871
2,826
2,794
Total Equity
- -
2.75
7.1
9.95
11.94
13.53
11.54
8.1
7.62
4.63
1.99
- -
- -
- -
Return on Invested Capital (%)
- -
4.71
9.13
12.37
13.5
15.08
12.95
9.23
8.24
4.97
2.49
- -
- -
- -
Return on Capital (%)
- -
6.53
11.64
14.6
15.79
17.79
15.61
10.27
9.55
5.81
2.63
0.46
-1.12
-2.91
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,079
1,116
1,212
LT Borrowings
416
371
402
LT Finance Leases
46
40
41
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
164
164
164
Market Capitalization
3,641
3,246
3,475

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,975
2,924
3,033
Cash, Cash Equivalents & STI
916
774
848
Accounts Receivable, Net
667
735
768
Inventories
1,056
1,058
1,080
Total Current Liabilities
1,529
1,610
1,671
Payables & Accruals
- -
- -
- -
ST Debt
1,079
1,116
1,212
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.98%
16.9%
-1.56%
Free Cash Flow
-44.99%
-4.66%
-83.81%
Net Income, GAAP
-21.4%
-87.42%
-339.82%
Sales/Revenue/Turnover
27.34%
14.91%
-12.56%
Total Cash Common Dividend
131.41%
85.89%
1.34%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
664
732
729
758
2,884
2025
604
615
- -
673
2,521
2026
583
683
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.03
0.02
0.08
2025
0.03
0.03
- -
-0.26
-0.19
2026
-0.2
-0.06
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.14
0.07
0.07
0.35
2025
0.08
0.13
- -
- -
0.35
2026
0.07
0.07
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Shanghai Titan Scientific Co., Ltd. (688133.SS) is a China-based company principally engaged in the research, development, production, and sales of laboratory products and supporting services for scientific researchers, quality control personnel, and industries including biomedicine, new materials, new energy, chemical chemistry, fine chemicals, food daily chemicals, analysis, and testing. The company offers core products and services encompassing scientific research reagents (high-end, general, analytical, biological), specialty chemicals (including organic compounds, inorganic compounds, intermediates, deuterated products, high-purity solvents), scientific research instruments and consumables (centrifuges, incubators, gel imaging systems, cell culture equipment, pipettes, chromatography consumables), safety and laboratory protective consumables, laboratory construction and integrated solutions (planning, design, procurement, installation, maintenance, relocation), and scientific research informatization software (such as Titan SRM and Titan LIMS); it operates through independent brands like Titan, TEDIA, Hzymes, Clinx, Magal, Radobio, and others, alongside third-party agency products via its Transoole.com platform. Founded in 2007 and headquartered at No. 89 Shilong Road, Xuhui District, Shanghai, China, the company maintains production bases in Songjiang and Fengxian, offices across 21 cities in China, and over 1,500 employees, with a focus on domestic supply chain security and global expansion. Recent developments include the 2024 acquisitions of RunDu Biology, MaiGao Instruments (centrifuges), and QinXiang Instruments, alongside establishing joint ventures Titan ChunYuan (pure water machines) and YiDa Biology (food rapid test reagents); in July 2025, it signed a letter of intent to acquire 100% of UK-based Apollo Scientific Ltd. (ASL) from Central Glass Co., Ltd. for approximately RMB 55.85 million to enhance overseas chemical reagent offerings and sales channels in Europe and the US; earlier, in 2021, it acquired a majority stake in Anhui TEDIA High Purity Solvents, expanding high-purity solvent capacity to 13,800 tons annually.